ES2707125T3 - 2,4-diamino-quinolina sustituida como nuevos agentes anticancerosos - Google Patents
2,4-diamino-quinolina sustituida como nuevos agentes anticancerosos Download PDFInfo
- Publication number
- ES2707125T3 ES2707125T3 ES15837091T ES15837091T ES2707125T3 ES 2707125 T3 ES2707125 T3 ES 2707125T3 ES 15837091 T ES15837091 T ES 15837091T ES 15837091 T ES15837091 T ES 15837091T ES 2707125 T3 ES2707125 T3 ES 2707125T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- substituted
- alkyl
- heteroatoms selected
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JICRJOOPMADODM-UHFFFAOYSA-N CC(C)(C)NC(CC1)CCN1c1cc(Nc(cc2)ccc2Cl)nc2ccccc12 Chemical compound CC(C)(C)NC(CC1)CCN1c1cc(Nc(cc2)ccc2Cl)nc2ccccc12 JICRJOOPMADODM-UHFFFAOYSA-N 0.000 description 2
- 0 CC(C)(C)NC1CCN(C*)CC1 Chemical compound CC(C)(C)NC1CCN(C*)CC1 0.000 description 1
- UDHYIHYYRQGULP-UHFFFAOYSA-N CC(C)(C)NC1CCN(Cc2ccccc2)CC1 Chemical compound CC(C)(C)NC1CCN(Cc2ccccc2)CC1 UDHYIHYYRQGULP-UHFFFAOYSA-N 0.000 description 1
- LBURSXFVLVLMIH-UHFFFAOYSA-N CC(C)(C)NC1CCNCC1 Chemical compound CC(C)(C)NC1CCNCC1 LBURSXFVLVLMIH-UHFFFAOYSA-N 0.000 description 1
- TWYPELXOXXFJIW-UHFFFAOYSA-N Clc(cc1)ccc1Nc1nc(cccc2)c2c(Cl)c1 Chemical compound Clc(cc1)ccc1Nc1nc(cccc2)c2c(Cl)c1 TWYPELXOXXFJIW-UHFFFAOYSA-N 0.000 description 1
- QNBJYUUUYZVIJP-UHFFFAOYSA-N Clc1c(cccc2)c2nc(Cl)c1 Chemical compound Clc1c(cccc2)c2nc(Cl)c1 QNBJYUUUYZVIJP-UHFFFAOYSA-N 0.000 description 1
- HDHQZCHIXUUSMK-UHFFFAOYSA-N Oc1c(cccc2)c2nc(O)c1 Chemical compound Oc1c(cccc2)c2nc(O)c1 HDHQZCHIXUUSMK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073325P | 2014-10-31 | 2014-10-31 | |
| PCT/IB2015/002438 WO2016067112A1 (en) | 2014-10-31 | 2015-10-26 | Substituted 2,4 diamino-quinoline as new anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2707125T3 true ES2707125T3 (es) | 2019-04-02 |
Family
ID=55404745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15837091T Active ES2707125T3 (es) | 2014-10-31 | 2015-10-26 | 2,4-diamino-quinolina sustituida como nuevos agentes anticancerosos |
Country Status (34)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3452465T1 (sl) * | 2016-05-04 | 2021-04-30 | Genoscience Pharma | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni |
| US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
| EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
| ES2979163T3 (es) | 2018-10-31 | 2024-09-24 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1 |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2022033465A1 (zh) * | 2020-08-10 | 2022-02-17 | 萧乃文 | 具有协同抗癌功效的氯硝柳胺和双硫仑医药组合物及其用途 |
| CN112375081B (zh) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用 |
| CN112876673B (zh) * | 2021-01-25 | 2021-12-24 | 山东大学 | 一种pH响应性纳米共聚物载体及其制备方法和应用 |
| EP4349336A1 (en) | 2022-10-04 | 2024-04-10 | Genoscience Pharma | Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers |
| EP4520396A1 (en) | 2023-09-05 | 2025-03-12 | Genoscience Pharma | Crystalline freebase form of 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopiperidin-1-yl)-quinoline and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8580301A1 (es) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| AU2003288994A1 (en) | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| EP1601357A4 (en) * | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
| UA121098C2 (uk) * | 2013-01-15 | 2020-04-10 | Інсайт Холдинґс Корпорейшн | Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази |
| US10179770B2 (en) * | 2013-03-18 | 2019-01-15 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
-
2015
- 2015-10-26 HR HRP20190107TT patent/HRP20190107T1/hr unknown
- 2015-10-26 DK DK15837091.6T patent/DK3212629T3/en active
- 2015-10-26 US US15/543,504 patent/US10722505B2/en active Active
- 2015-10-26 GE GEAP201514494A patent/GEP20207108B/en unknown
- 2015-10-26 TN TN2017000168A patent/TN2017000168A1/en unknown
- 2015-10-26 EA EA201790949A patent/EA037119B1/ru unknown
- 2015-10-26 ES ES15837091T patent/ES2707125T3/es active Active
- 2015-10-26 PL PL15837091T patent/PL3212629T3/pl unknown
- 2015-10-26 CN CN201580058830.2A patent/CN107148416B/zh active Active
- 2015-10-26 JP JP2017522809A patent/JP6588546B2/ja active Active
- 2015-10-26 AU AU2015338844A patent/AU2015338844B2/en active Active
- 2015-10-26 MY MYPI2017000628A patent/MY193740A/en unknown
- 2015-10-26 CA CA2965262A patent/CA2965262C/en active Active
- 2015-10-26 CR CR20170177A patent/CR20170177A/es unknown
- 2015-10-26 SG SG11201703479SA patent/SG11201703479SA/en unknown
- 2015-10-26 PT PT15837091T patent/PT3212629T/pt unknown
- 2015-10-26 EP EP15837091.6A patent/EP3212629B1/en active Active
- 2015-10-26 SI SI201530566T patent/SI3212629T1/sl unknown
- 2015-10-26 RS RS20190110A patent/RS58328B1/sr unknown
- 2015-10-26 UA UAA201705278A patent/UA122062C2/uk unknown
- 2015-10-26 MA MA40875A patent/MA40875B1/fr unknown
- 2015-10-26 WO PCT/IB2015/002438 patent/WO2016067112A1/en not_active Ceased
- 2015-10-26 KR KR1020177013639A patent/KR102548547B1/ko active Active
- 2015-10-26 LT LTEP15837091.6T patent/LT3212629T/lt unknown
- 2015-10-26 TR TR2019/00148T patent/TR201900148T4/tr unknown
-
2017
- 2017-04-18 IL IL251775A patent/IL251775B/en active IP Right Grant
- 2017-04-27 DO DO2017000107A patent/DOP2017000107A/es unknown
- 2017-04-28 CL CL2017001073A patent/CL2017001073A1/es unknown
- 2017-04-28 EC ECIEPI201726748A patent/ECSP17026748A/es unknown
- 2017-04-28 NI NI201700052A patent/NI201700052A/es unknown
- 2017-05-02 PH PH12017500810A patent/PH12017500810A1/en unknown
- 2017-07-24 CO CONC2017/0007325A patent/CO2017007325A2/es unknown
- 2017-08-31 PE PE2017001484A patent/PE20191142A1/es unknown
-
2019
- 2019-01-17 CY CY20191100067T patent/CY1121326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2707125T3 (es) | 2,4-diamino-quinolina sustituida como nuevos agentes anticancerosos | |
| AU2014233757B2 (en) | Quinolines derivatives as novel anticancer agents | |
| US20230233692A1 (en) | Compounds for targeted degradation of ret | |
| EP3966207A1 (en) | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
| KR20240018446A (ko) | 돌연변이 braf의 분해를 위한 요법 | |
| BR112017018637B1 (pt) | Composto e seus usos, composição farmacêutica e seus usos e kit para tratamento e prevenção de doenças neoplásicas e não neoplásicas proliferativas | |
| NZ731345B2 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| HK1240587B (zh) | 作为新抗癌药的被取代的2，4二氨基-喹啉 | |
| HK1240587A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| WO2024030968A1 (en) | Compounds for modulating ret protein | |
| WO2024179547A1 (en) | Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof | |
| KR20250145679A (ko) | Ret 키나제의 분해제로서의 이소인돌리논 글루타르이미드 및 페닐 글루타르이미드 유사체 |